Solid Tumor Clinical Trials in Iowa City, Iowa

6 studies are recruiting for solid tumor in Iowa City, Iowa right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies now recruiting

1. Study of RYZ401 in Subjects With Solid Tumors Expressing SSTRs.

   The primary objectives are to determine the recommended Phase 2 dose (RP2D) and optimal treatment regimen, characterize safety and tolerability, and evaluate preliminary efficacy of RYZ401 in subjects with NETs and other selected solid tumors expressing SSTRs.

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Research Facility, Iowa City, Iowa

   Locations

   14 in total

   Run by

   RayzeBio, Inc.

   See if you can join NCT07165132 on ClinicalTrials.gov

2. Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist)

   This is a Phase 1/2, open-label, non-randomized, 4-part trial to determine the safety profile and identify the maximum tolerated dose (MTD) and/or recommended Phase 2 dose (RP2D) of INBRX 106 administered as a single agent or in combination with the anti-PD-1 checkpoint inhibitor (CPI) pembrolizuma…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   University of Iowa, Iowa City, Iowa

   Locations

   42 in total

   Run by

   Inhibrx Biosciences, Inc

   See if you can join NCT04198766 on ClinicalTrials.gov

3. A Study of 177Lu-FAP-2286 in Advanced Solid Tumors

   Fibroblast activation protein (FAP) is a cell surface protein that is highly expressed on the surface of cancer-associated fibroblasts (CAFs) present in the tumor microenvironment of most epithelial cancers, whereas limited expression of FAP is observed in normal tissues. In some cancers of mesench…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   University of Iowa Hospitals and Clinics, Iowa City, Iowa

   Locations

   41 in total

   Run by

   Novartis Pharmaceuticals

   See if you can join NCT04939610 on ClinicalTrials.gov

4. A First-in-human, Dose Escalation and Dose Expansion Study of SAR445877 in Adult Participants With Advanced Solid Tumors

   This is a Phase 1/2, open label, multiple cohort study to assess the safety and preliminary efficacy of SAR445877 as a monotherapy or in combination with other anticancer therapies for participants aged at least 18 years with advanced unresectable or metastatic solid tumors. The study will include …

   Stage

   Phase 1

   Ages

   18 and older

   Site

   University of Iowa- Site Number : 8400014, Iowa City, Iowa

   Locations

   22 in total

   Run by

   Sanofi

   See if you can join NCT05584670 on ClinicalTrials.gov

5. 5-Azacitidine Plus PD-1/PD-L1 Inhibitor With PD-1/PD-L1 Refractory Tumors

   This is a Phase I study to determine the optimal biological dose (OBD) of 5-Azacitidine in combination with PD-1/PD-L1 inhibitors in patients with tumors refractory to PD-1/PD-L1 inhibitors, for which such treatments have been approved.

   Stage

   Phase 1

   Ages

   18 to 99

   Site

   University of Iowa Health Care, Iowa City, Iowa

   Run by

   Mohammed Milhem

   See if you can join NCT07404332 on ClinicalTrials.gov

6. Safety and Preliminary Efficacy of OBT076 in Recurrent/Metastatic CD205+ Solid Tumors

   The purpose of this study is to evaluate OBT076, which is a drug that combines an antibody with an anti-cancer drug. This class of drugs are called Antibody-Drug Conjugates (ADC). Antibodies are normally produced in the human body by the immune system to fight infections but can be designed to targ…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   The State University of Iowa, Iowa City, Iowa

   Locations

   27 in total

   Run by

   Oxford BioTherapeutics Ltd

   See if you can join NCT04064359 on ClinicalTrials.gov